GCP
PVLA

GSA Capital Partners’s Palvella Therapeutics PVLA Stock Holding History

GSA Capital Partners’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,563
Closed -$380K – 1995
2022
Q4 		$380K Buy
+4,563
New +$367K 0.05% 784
2021
Q2 		– Sell
-979
Closed -$201K – 1641
2021
Q1 		$201K Buy
+979
New +$214K 0.03% 909
2020
Q3 		– Sell
-165
Closed -$41K – 1419
2020
Q2 		$41K Sell
165
-1,772
-91% -$414K 0.02% 542
2020
Q1 		$353K Sell
1,937
-505
-21% -$127K 0.09% 379
2019
Q4 		$707K Buy
+2,442
New +$677K 0.08% 418
2019
Q3 		– Sell
-740
Closed -$278K – 1762
2019
Q2 		$278K Sell
740
-476
-39% -$142K 0.03% 1047
2019
Q1 		$326K Sell
1,216
-268
-18% -$63.7K 0.03% 945
2018
Q4 		$316K Sell
1,484
-2,904
-66% -$901K 0.04% 812
2018
Q3 		$1.97M Buy
4,388
+1,014
+30% +$441K 0.11% 252
2018
Q2 		$1.37M Buy
3,374
+3,165
+1,514% +$1.51M 0.07% 525
2018
Q1 		$114K Hold
209
– – 0.01% 1523
2017
Q4 		$126K Buy
+209
New +$97.2K 0.01% 1464

Other funds holding PVLA

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

GSA Capital Partners's PVLA Position: Q1 2023 in Review

GSA Capital Partners sold out of Palvella Therapeutics (PVLA) in Q1 2023, closing a stake of 4,563 shares — an estimated $380K sold.

GSA Capital Partners first reported a position in PVLA in Q4 2017 and held it in 12 quarters. The position peaked at $1.97M in Q3 2018. 60 funds tracked by Wall St. Rank hold PVLA as of Q1 2023.

  • GSA Capital Partners reported no remaining Palvella Therapeutics position as of Q1 2023 after selling out during the quarter.
  • GSA Capital Partners sold 4,563 Palvella Therapeutics shares in Q1 2023, an estimated $380K.
  • GSA Capital Partners first reported a position in Palvella Therapeutics in Q4 2017 and held it in 12 quarters.
  • GSA Capital Partners's Palvella Therapeutics position peaked at $1.97M in Q3 2018.
  • 60 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2023.

Based on GSA Capital Partners's 13F filing for Q1 2023, filed 12 May 2023.